Oncotype DX, created by Genomic Health, is a diagnostic test that quantifies the likelihood of disease recurrence in women with early-stage breast cancer and assesses the likely benefit from certain types of chemotherapy. Oncotype DX was developed for women with early-stage invasive breast cancer who are ER+ and whose lymph nodes are negative (do not contain tumor). Typically in these cases, treatment with hormonal therapy, such as tamoxifen, is planned.

PropertyValue
dbpprop:abstract
  • Oncotype DX, created by Genomic Health, is a diagnostic test that quantifies the likelihood of disease recurrence in women with early-stage breast cancer and assesses the likely benefit from certain types of chemotherapy. Oncotype DX was developed for women with early-stage invasive breast cancer who are ER+ and whose lymph nodes are negative (do not contain tumor). Typically in these cases, treatment with hormonal therapy, such as tamoxifen, is planned. Oncotype DX is not appropriate for use in patients with carcinoma in situ (precancerous) or metastatic breast cancer (cancer that has spread beyond the breast). Oncotype DX analyzes a panel of 21 genes within a tumor to determine a Recurrence Score. The Recurrence Score is a number between 0 and 100 that corresponds to a specific likelihood of breast cancer recurrence within 10 years of the initial diagnosis. With this information, it may be possible for doctors and patients to make more informed decisions about breast cancer treatment options. Oncotype DX is a noninvasive test that is performed on a small amount of the tissue removed during the original surgery lumpectomy, mastectomy, or core biopsy, which means no additional invasive procedure is required. After the surgical procedure, the tissue sample is fixed in formalin and embedded in paraffin so it can be preserved for further diagnostic testing. To perform Oncotype DX, the pathologist will send several thin sections of the formalin-fixed, paraffin-embedded tissue sample to Genomic Health. Oncotype DX uses a highly reproducible laboratory process known as RT-PCR to determine the expression of the 21-gene panel. The Oncotype DX test results are then integrated with other laboratory test results to help doctors formulate a treatment plan based on the unique characteristics of the tumor.
dbpprop:hasPhotoCollection
dbpprop:reference
rdf:type
rdfs:comment
  • Oncotype DX, created by Genomic Health, is a diagnostic test that quantifies the likelihood of disease recurrence in women with early-stage breast cancer and assesses the likely benefit from certain types of chemotherapy. Oncotype DX was developed for women with early-stage invasive breast cancer who are ER+ and whose lymph nodes are negative (do not contain tumor). Typically in these cases, treatment with hormonal therapy, such as tamoxifen, is planned.
rdfs:label
  • Oncotype DX
owl:sameAs
skos:subject
foaf:homepage
foaf:page
is dbpprop:redirect of
is owl:sameAs of